Tesamorelin & Ipamorelin Blend (8mg)

Tesamorelin & Ipamorelin Blend (8mg) is a pre-weighed combination of complementary peptides in a single vial, synthesized and lyophilized in the USA.

Each vial of Tesamorelin & Ipamorelin Blend (8mg) contains a pre-weighed ratio of Tesamorelin 4mg, Ipamorelin 4mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Investigations of Tesamorelin & Ipamorelin Blend (8mg) commonly measure secretagogue activity and downstream signaling markers in controlled cell models.

Researchers pair Tesamorelin & Ipamorelin Blend (8mg) with pulse-profile analysis to characterize its release dynamics under standardized conditions.

Comparative studies of Tesamorelin & Ipamorelin Blend (8mg) often benchmark its potency against reference peptides in the same family.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Tesamorelin & Ipamorelin Blend (8mg). Summaries are provided for orientation only and reflect the cited sources.

Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data^[1] — This pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials evaluated the effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. The authors combined trial data, including safety extension information, to assess changes in visceral adiposity. The findings suggested that tesamorelin may reduce visceral adipose tissue in this patient population. (The Journal of Clinical Endocrinology & Metabolism 2010)

Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial^[2] — This randomized clinical trial examined the effect of tesamorelin on liver fat and visceral fat in HIV-infected patients with abdominal fat accumulation. The authors measured hepatic and visceral adiposity before and after treatment in the randomized comparison. The results indicated that tesamorelin may favorably affect both liver and visceral fat in these patients. (JAMA 2014)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[3] — This study tested whether the novel growth-hormone-releasing peptide ipamorelin can stimulate longitudinal bone growth in rats. The authors examined the peptide's effects on skeletal growth over the study period. The results suggested that ipamorelin promotes bone elongation, consistent with its GH-releasing activity. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[4] — This pharmacokinetic study evaluated ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to their absorption after nasal administration. The authors compared the pharmacokinetic profiles of these peptides to assess their suitability for non-invasive delivery. The findings indicated that nasal absorption characteristics vary among the secretagogues examined. (Xenobiotica 1999)

References

1. Falutz J, et al.. "Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data." The Journal of Clinical Endocrinology & Metabolism. 2010. academic.oup.com/jcem/article-pdf/95/9/4291/10413652/jcem4291.…
2. Stanley TL, et al.. "Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial." JAMA. 2014. pmc.ncbi.nlm.nih.gov/articles/PMC4363137/
3. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
4. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.